Venaxis Inc (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well, with sensitivity and negative predictive value results that exceeded those from the previous pilot study. The company believes these pivotal results are sufficient for potential FDA clearance and expects to finalize its 510(k) submission and file with the FDA in the next few weeks. Venaxis Inc (NASDAQ:APPY) stock opened at $3.31 in last trading session, and closed at $3.29, trading in the range of $3.25 – $3.88. The stock showed a positive weekly performance of 27.03%.
(Mar 7th, 2014)Zacks initiated coverage on shares of Celladon Corp (NASDAQ:CLDN) in a report released on Wednesday, AmericanBankingNews.com reports. The firm set a “hold” rating on the stock. Celladon Corp (NASDAQ:CLDN) shares closed at $14.66 on last trade day, by gaining 8.27%. Stock 52 week range is $7.45 – $15.48. Company’s market capitalization is $271.21 million.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)was a big mover last session, as the company saw its shares rise by roughly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 30% in the past one-month time frame. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock advanced 9.63% and finished the last session at $17.53. The EPS of the stock remained -0.66. Company’s market capitalization is $587.29 million.
Oncothyreon Inc (USA) (NASDAQ:ONTY) reported financial results for the year and quarter ended December 31, 2013. Loss from operations was $41.2 million for the year ended December 31, 2013 compared with $28.5 million for the year ended December 31, 2012. Net loss for the year ended December 31, 2013 was $38.8 million, or $0.62 per basic and diluted share, compared with net loss of $3.4 million, or $0.06 per basic and $0.53 per diluted share, for the year ended December 31, 2012. The increase in net loss was primarily attributable to the difference in the change in the fair value of warrant liability, with $2.3 million in non-cash income for the year ended December 31, 2013, compared with $25.5 million in non-cash income for the prior year. Research and development expenses also increased, primarily due to the $10.0 million upfront payment to Array. Oncothyreon Inc (USA) (NASDAQ:ONTY) stock opened at $3.90 in last trading session and closed at $3.89. The 52 week range of the stock is $1.55 – $4.08 and the day range was $3.80 – $4.08.